Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- Keywords
- Inflammatory bowel disease, SARS-CoV-2, herd immunity,
- MeSH
- Ambulatory Care Facilities organization & administration MeSH
- COVID-19 MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Disease Outbreaks prevention & control MeSH
- Risk Assessment MeSH
- Occupational Health * MeSH
- Inflammatory Bowel Diseases epidemiology immunology therapy MeSH
- Immunoglobulin G analysis immunology MeSH
- Clinical Laboratory Techniques methods statistics & numerical data MeSH
- Immunity, Herd MeSH
- Coronavirus Infections diagnosis epidemiology prevention & control MeSH
- Humans MeSH
- Needs Assessment MeSH
- Pandemics prevention & control statistics & numerical data MeSH
- Infectious Disease Transmission, Patient-to-Professional prevention & control MeSH
- Antibodies, Viral immunology MeSH
- Seroepidemiologic Studies MeSH
- COVID-19 Testing MeSH
- Pneumonia, Viral epidemiology prevention & control MeSH
- Health Personnel MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Germany MeSH
- Names of Substances
- Immunoglobulin G MeSH
- Antibodies, Viral MeSH
Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spread worldwide triggering a pandemic during the year 2020. The proportion of persons infected with SARS-CoV-2 whose infection remained subclinical is not known. However, such information is important to determine whether the control measures currently employed are sufficient to halt the spread of the virus. Current study has examined the seroprevalence of anti-SARS-CoV-2 antibodies in a population of 92 healthcare professionals working with patients with inflammatory bowel disease (IBD). The enzyme-linked immunosorbent assay (ELISA) test system for SARS-CoV-2 IgG from EUROIMMUN Medizinische Labordiagnostika AG (Germany) was used. Very low herd antibody-mediated immunity was proven, less than 2%, although we have been faced with the COVID-19 pandemic for several months. Anti-SARS-CoV-2 IgG antibody testing is currently unable to provide sufficient information about our anti-infectious immunity.
Clinical and Research Center for Inflammatory Bowel Disease ISCARE a s Prague Czech Republic
References provided by Crossref.org
